Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma
Osteosarcoma is the most common primary bone tumor, yet there have been no substantial advances in treatment or survival in three decades. We examined 59 tumor/normal pairs by whole-exome, whole-genome, and RNA-sequencing. Only the TP53 gene was mutated at significant frequency across all samples. T...
Main Author: | Lander, Eric Steven |
---|---|
Other Authors: | Massachusetts Institute of Technology. Department of Biology |
Format: | Article |
Language: | en_US |
Published: |
National Academy of Sciences (U.S.)
2015
|
Online Access: | http://hdl.handle.net/1721.1/97586 |
Similar Items
-
Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma
by: Eun Jin Sun, et al.
Published: (2021-11-01) -
RILP inhibits tumor progression in osteosarcoma via Grb10-mediated inhibition of the PI3K/AKT/mTOR pathway
by: Zhun Wei, et al.
Published: (2023-10-01) -
Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer
by: Huayi Li, et al.
Published: (2021-07-01) -
Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer
by: Carla L. Alves, et al.
Published: (2023-02-01) -
Targeting the PI3K/Akt/mTOR Signaling Pathway: Applications of Nanotechnology
by: Forough Alemi Serej, et al.
Published: (2018-01-01)